Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 3.71M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -23.86M | Forward P/E | -16.63 | EPS next Y | - | 50D Avg Chg | -38.00% |
| Sales | 5.02M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -85.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -95.00% |
| Recommedations | 3.00 | Quick Ratio | 0.04 | Shares Outstanding | 9.36M | 52W Low Chg | 4.00% |
| Insider Own | 7.81% | ROA | -104.50% | Shares Float | 9.14M | Beta | 1.28 |
| Inst Own | 16.59% | ROE | - | Shares Shorted/Prior | 98.94K/57.65K | Price | 1.33 |
| Gross Margin | -23.15% | Profit Margin | - | Avg. Volume | 873,820 | Target Price | - |
| Oper. Margin | -373.62% | Earnings Date | Nov 13 | Volume | 23,855,541 | Change | -66.67% |
About Adamis Pharmaceuticals Corporat
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Moss Ronald B. | Chief Medical Office.. Chief Medical Officer | Mar 18 | Sell | 0.6036 | 8,199 | 4,949 | 201,911 | 03/22/22 |
| Marguglio David J. | SVP and Chief Busine.. SVP and Chief Business Officer | Mar 18 | Sell | 0.6001 | 11,859 | 7,117 | 233,906 | 03/22/22 |
| CARLO DENNIS J PHD | President & CEO President & CEO | Mar 18 | Sell | 0.5993 | 10,490 | 6,287 | 285,867 | 03/22/22 |
| Benedicto David C. | Chief Financial Offi.. Chief Financial Officer | Mar 18 | Sell | 0.6128 | 3,603 | 2,208 | 39,875 | 03/22/22 |